Lilly links lepodisiran to durably lower lipoprotein in phase 2, providing edge over Amgen and Novartis

Eli Lilly has linked lepodisiran to sustained reductions in a cardiovascular disease risk factor for nearly 1.5 years, bolstering the company’s argument that the siRNA candidate has an edge over rivals from Amgen and Novartis.

The phase 2 trial tested the effect of lepodisiran on lipoprotein(a) (Lp(a)). Studies suggest…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks